JP6557166B2 - Nitrated proteolytic agent - Google Patents
Nitrated proteolytic agent Download PDFInfo
- Publication number
- JP6557166B2 JP6557166B2 JP2016072475A JP2016072475A JP6557166B2 JP 6557166 B2 JP6557166 B2 JP 6557166B2 JP 2016072475 A JP2016072475 A JP 2016072475A JP 2016072475 A JP2016072475 A JP 2016072475A JP 6557166 B2 JP6557166 B2 JP 6557166B2
- Authority
- JP
- Japan
- Prior art keywords
- nitrated
- tea
- protein
- extract
- meteorite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002797 proteolythic effect Effects 0.000 title claims description 5
- 239000000284 extract Substances 0.000 claims description 31
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 claims description 10
- 241001122767 Theaceae Species 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 244000269722 Thea sinensis Species 0.000 description 37
- 235000013616 tea Nutrition 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 14
- 210000000434 stratum corneum Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000004383 yellowing Methods 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 235000019225 fermented tea Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 235000006468 Thea sinensis Nutrition 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000006396 nitration reaction Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- -1 aromatic amino acids Chemical class 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 108091006003 carbonylated proteins Proteins 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000020339 pu-erh tea Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- KNUPSOXBESCJLY-UHFFFAOYSA-N 2-methoxy-1-phenylhexan-1-one Chemical compound CCCCC(OC)C(=O)C1=CC=CC=C1 KNUPSOXBESCJLY-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- OMBRFUXPXNIUCZ-UHFFFAOYSA-N dioxidonitrogen(1+) Chemical compound O=[N+]=O OMBRFUXPXNIUCZ-UHFFFAOYSA-N 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、ニトロ化タンパク質分解に関し、更に詳しくは碁石茶(登録商標)抽出物を含有するニトロ化タンパク質分解剤、ニトロ化チロシン分解剤、黄くすみ改善剤に関する。以下、ニトロ化タンパク質を単にニトロ化タンパクと称する場合があるが、同義である。
The present invention relates to nitrated proteolysis, and more particularly to a nitrated proteolytic agent, a nitrated tyrosine decomposer, and a yellowing dullness improving agent containing Soseki Tea (registered trademark) extract. Hereinafter, the nitrated protein may be simply referred to as nitrated protein, but it is synonymous.
タンパク質のニトロ化とは、生体内で発生した活性窒素種によって生じるタンパク質翻訳後修飾のひとつであり、タンパク質を構成する芳香族アミノ酸のチロシン、トリプトファンの残基中のベンゼン環にニトロ基が付与されたものである。ニトロ化反応はアミノ酸中のベンゼン環が、活性窒素種により形成されるニトロニウムイオン(NO2+)や二酸化窒素ラジカルなどと求電子置換反応をおこすことで生じる(非特許文献1)。生体内に存在する多くのタンパク質中のトリプトファンの含有率はチロシンのそれよりもはるかに小さく、タンパク質のニトロ化反応は主にチロシン残基に生じると考えられている(非特許文献2)。
タンパク質のニトロ化が起きると、酵素やチロシンキナーゼ型受容体の機能低下を引き起こすことで、細胞機能に影響を及ぼすことが知られる(非特許文献3)。また、タンパク質中のニトロチロシンは加齢に伴う数々の疾患(動脈硬化や脳虚血疾患など)で蓄積することが知られており、これらの疾患に関与することが報告されている(非特許文献4)。
Protein nitration is a post-translational modification of proteins caused by reactive nitrogen species generated in vivo. Nitro groups are added to the benzene rings in the tyrosine and tryptophan residues of the aromatic amino acids that make up proteins. It is a thing. The nitration reaction occurs when the benzene ring in the amino acid undergoes an electrophilic substitution reaction with a nitronium ion (NO2 +) or a nitrogen dioxide radical formed by active nitrogen species (Non-patent Document 1). The content of tryptophan in many proteins existing in the living body is much smaller than that of tyrosine, and it is considered that the nitration reaction of proteins mainly occurs at tyrosine residues (Non-patent Document 2).
It is known that when protein nitration occurs, cell functions are affected by causing functional degradation of enzymes and tyrosine kinase receptors (Non-patent Document 3). In addition, nitrotyrosine in proteins is known to accumulate in many diseases associated with aging (such as arteriosclerosis and cerebral ischemic disease), and has been reported to be involved in these diseases (non-patented) Reference 4).
皮膚では加齢に伴い、シワ、たるみ、シミ、くすみ等の変化が生じる。
くすみにはさまざまな種類があり、透明感の減少によるくすみ(皮膚表面の凹凸による影によるもの、角層肥厚による光透過性の低下によるもの、皮膚表面での乱反射によるつやの低下によるものなど)、皮膚の赤みの低下によるくすみ(血行不良による)、皮膚の色ムラによるくすみ(メラニンの不均一性)、加齢に伴う皮膚の黄みの増加によるくすみなどがある(非特許文献5)。
中でも加齢に伴う皮膚色の黄み(b*)の増加は、黄ぐすみとして知られ、老化に伴う特徴的な皮膚の色調変化である。従来、黄ぐすみの主な原因は、真皮中に存在するエラスチンやコラーゲン等のタンパク質の糖化物(特許文献1)やタンパク質のカルボニル化物(特許文献2)であると考えられていた。
Skin changes with wrinkles, sagging, spots, dullness, etc. with aging.
There are various types of dullness, such as dullness due to reduced transparency (such as due to shadows due to irregularities on the skin surface, due to reduced light transmission due to thickening of the stratum corneum, due to reduced gloss due to irregular reflection on the skin surface), There are dullness due to a decrease in redness of the skin (due to poor circulation), dullness due to uneven skin color (non-uniformity of melanin), dullness due to an increase in yellowness of the skin with aging (Non-patent Document 5).
In particular, the increase in yellowness (b *) of skin color with aging is known as yellowing and is a characteristic skin tone change with aging. Conventionally, the main cause of yellowing was thought to be a glycated product of proteins such as elastin and collagen (Patent Document 1) and a carbonylated protein (Patent Document 2) present in the dermis.
ニトロ化タンパク生成に伴う各種疾患を改善するため、ペルオキシナイトライトを消去する効果成分の提案や(特許文献3)や、チオール基をもつ物質によるペルオキシナイトライト補足する効果成分の提案(特許文献4)がなされてきた。しかしながら、これらはすべて専らニトロ化タンパクの生成を抑制するのみであり、出来てしまったニトロ化タンパクに対しては何らの改善もされていない。その為、ニトロ化タンパク生成に伴う各種疾患の根本的な解決に至っていない。 In order to improve various diseases associated with the production of nitrated proteins, a proposal of an effective component for eliminating peroxynitrite (Patent Document 3) and an effective component for supplementing peroxynitrite with a substance having a thiol group (Patent Document 4) ) Has been made. However, all of these only inhibit the production of nitrated proteins, and no improvement is made for the nitrated proteins that have been produced. Therefore, the fundamental solution of various diseases associated with the production of nitrated proteins has not been achieved.
一方、碁石茶は、チャノキ(Camellia sinensis)の葉を収穫後、蒸して自然発酵を停止させ、その後、むしろの中で寝かす間に好気性カビ、桶に浸ける間に嫌気性バクテリアによって発酵を行う、二段発酵茶である。碁石茶中に含まれる成分としては、アスコルビン酸やカテキン化合物が他の茶類と比較して少なく、特有の活性成分を含む可能性が指摘されており、高脂血症及び動脈硬化抑制効果(非特許文献6)、動血圧上昇抑制効果(特許文献5)が知られているが、ニトロ化タンパクの分解効果については全く知られていなかった。 On the other hand, meteorite tea, after harvesting the leaves of Camellia sinensis, is steamed to stop spontaneous fermentation, and then fermented by aerobic mold while sleeping in it, and by anaerobic bacteria while immersed in straw A two-stage fermented tea. As the ingredients contained in Goseki tea, ascorbic acid and catechin compounds are less than other teas, and it has been pointed out that it may contain unique active ingredients. Non-patent document 6), the effect of suppressing the increase in dynamic blood pressure (patent document 5) is known, but the degradation effect of nitrated protein was not known at all.
このような状況下、発明者らは、ニトロ化タンパク生成に伴う各種疾患を根本的に解決するには、単にその生成を抑制するのではなく、出来てしまったニトロ化タンパクを分解することこそが、根本的解決につながるとの結論に至った。 Under these circumstances, in order to fundamentally solve various diseases associated with the production of nitrated proteins, the inventors do not simply suppress the production but to decompose the nitrated protein that has been produced. However, it was concluded that it would lead to a fundamental solution.
合わせて、黄ぐすみの原因に関し研究を行ったところ、黄ぐすみの原因は、従来考えられていた真皮中に存在するタンパク質の糖化物やカルボニル化物だけではなく、角層中に存在するタンパク質を構成するアミノ酸がニトロ化されることによって生じるニトロ化タンパクが大きな原因となっていることを解明し、更には碁石茶抽出物によって当該ニトロ化タンパクを分解することが出来ることを突き止め、発明完成に至った。 In addition, when research was conducted on the cause of yellowing, the cause of yellowing was not only glycated or carbonylated proteins in the dermis, but also proteins in the stratum corneum. Clarified that the nitrated protein produced by the nitration of the amino acids that make up the protein is a major cause, and further found that the nitrated protein can be decomposed by the meteorite tea extract. It came to.
本発明は、出来てしまったニトロ化タンパクを分解する成分を提供することを課題とする。 This invention makes it a subject to provide the component which decomposes | disassembles the nitrated protein which has been completed.
本発明者らは、碁石茶抽出物を用いることで上記課題を解決した。 The present inventors have solved the above problems by using a meteorite tea extract.
本願発明によれば、出来てしまったニトロ化タンパクを分解することが出来、ニトロ化タンパクに起因する動脈硬化や脳虚血疾患、細胞機能低下、黄ぐすみ等の各種症状を改善することが出来る。 According to the present invention, the nitrated protein that has been produced can be decomposed, and various symptoms such as arteriosclerosis and cerebral ischemic disease, cellular function decline, and yellowing caused by the nitrated protein can be improved. I can do it.
本発明の実施の形態について説明する前に、本発明者らが得た新知見について説明する。 Before describing the embodiments of the present invention, new knowledge obtained by the present inventors will be described.
<黄ぐすみの要因の特定>
発明者らは、以下の方法により黄ぐすみの原因が、角層中のタンパク質がニトロ化されることにより生成されるニトロ化タンパクであることを突き止めた。
<Identification of the cause of yellowing>
The inventors have determined that the cause of yellowing due to the following method is a nitrated protein produced by the nitrated protein in the stratum corneum.
<実験方法>
事前に測定内容に同意を得た20、30、40、50代の女性(各4−5名)を被験者に、頬部の皮膚色を分光測色計(CM−700d、コニカミノルタ)にて測定し、頬部角層の採取を行った。角層の採取は、頬部に粘着テープ(スリーエム製)を接着し、角層を採取した。角層が接着したテープを約3 mm四方に細切し、溶出バッファー(100 mM Tris/HCl (pH 8.0)、140 mM NaCl、0.1% Tween−20、10 μg/mL アプロチニン、1 mM phenylmethylsulfonyL fluoride)が入ったチューブに混合した。この混合物を超音波処理することで、テープから角層タンパク質をバッファー中に溶出した。溶出溶液を新しいチューブに移して遠心操作を行い、上清を回収したものを角層抽出物サンプルとした。
角層抽出物サンプル中の3−ニトロチロシン量はNWLSSTM Nitrotyrosine ELISA(Northwest Life Science Specialities)を用いて定量し、角層抽出物サンプルのタンパク質量はBCA法にて定量した。3−ニトロチロシン量をタンパク質量で除したものを、角層タンパク質あたりの3−ニトロチロシン量とした。
<Experiment method>
Females in their 20s, 30s, 40s and 50s (4-5 people each) who had consented to the measurement content in advance, and the skin color of the cheeks with a spectrocolorimeter (CM-700d, Konica Minolta) Measurement was made and the cheek stratum corneum was collected. The stratum corneum was collected by attaching an adhesive tape (manufactured by 3M) to the cheek and collecting the stratum corneum. The tape to which the stratum corneum is adhered is cut into approximately 3 mm squares, and the elution buffer (100 mM Tris / HCl (pH 8.0), 140 mM NaCl, 0.1% Tween-20, 10 μg / mL aprotinin, 1 The mixture was mixed into a tube containing mM phenylmethylsulfurylfluoride). The mixture was sonicated to elute stratum corneum protein from the tape into the buffer. The elution solution was transferred to a new tube and centrifuged, and the supernatant was collected as a stratum corneum extract sample.
The amount of 3-nitrotyrosine in the stratum corneum extract sample was quantified using NWLSS ™ Nitrotyrosine ELISA (Northwest Life Science Specialties), and the protein amount of the stratum corneum extract sample was quantified by the BCA method. The amount of 3-nitrotyrosine divided by the amount of protein was defined as the amount of 3-nitrotyrosine per stratum corneum protein.
<結果>
頬部の角層タンパク質あたりの3−ニトロチロシン量と皮膚色の黄み(b*値)の関係について、ピアソンの相関関係の検定を行ったところ、これらに正の相関関係にあることが明らかとなり、角層にニトロ化タンパク質が多いほど、頬部の皮膚は黄色化することが強く示された(図1)。
<Result>
Pearson's correlation test was performed on the relationship between the amount of 3-nitrotyrosine per cheek stratum corneum protein and the yellowness of the skin color (b * value). It was strongly shown that the more nitrated protein in the stratum corneum, the more yellow the skin on the cheeks (FIG. 1).
この結果を年齢層別に分析すると、表1に示すとおり、20〜30代の層より、40〜50代の層の方が、ニトロ化タンパクの量と皮膚色の黄み(b*値)間の相関関係が高いことが分かった。
このことから、ニトロ化タンパクを分解できれば、肌の黄ぐすみを改善できることは勿論のこと、その素材の効果はより高い年齢層における肌の黄みの改善に期待出来ると言える。
When this result is analyzed according to age group, the amount of nitrated protein and the yellowness of the skin color (b * value) are higher in the 40-50 generation layer than in the 20-30 generation layer, as shown in Table 1. It was found that the correlation of was high.
From this, it can be said that if the nitrated protein can be decomposed, the yellowing of the skin can be improved, and the effect of the material can be expected to improve the yellowing of the skin in an older age group.
本発明で使用する碁石茶は、チャノキ(Camellia sinensis)の葉を収穫後、蒸して自然発酵を停止させ、その後、むしろの中で寝かす間に好気性カビ、桶に浸ける間に嫌気性バクテリアによって発酵を行う、二段発酵茶である。高知県で伝統的に製造されているので、市販品を使用することができる他、特開2014-43406号や、特開2009-183272号等に記載の方法で製造して得ることもできる。 The meteorite tea used in the present invention is obtained by harvesting the leaves of Camellia sinensis, steaming it to stop natural fermentation, and then rather than aerobic mold while sleeping in it, anaerobic bacteria while soaking A two-stage fermented tea that is fermented. Since it is traditionally produced in Kochi Prefecture, it is possible to use a commercially available product, or it can be produced by the method described in JP-A-2014-43406, JP-A-2009-183272, or the like.
碁石茶抽出物の調製は特に限定されないが、例えば種々の適当な有機溶媒を用いて、低温下から加温下で抽出される。抽出溶媒としては、例えば、水;メチルアルコール、エチルアルコール等の低級1価アルコール;グリセリン、プロピレングリコール、1,3−ブチレングリコール等の液状多価アルコール;アセトン、メチルエチルケトン等のケトン;酢酸エチルなどのアルキルエステル;ベンゼン、ヘキサン等の炭化水素;ジエチルエーテル等のエーテル類;ジクロルメタン、クロロホルム等のハロゲン化アルカン等の1種または2種以上を用いることが出来る。就中、水、エチルアルコール、1,3−ブチレングリコールの1種または2種以上の混合溶媒が特に好適である。 The preparation of the meteorite tea extract is not particularly limited, and for example, it is extracted from a low temperature to a warm temperature using various appropriate organic solvents. Examples of the extraction solvent include water; lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol; ketones such as acetone and methyl ethyl ketone; and ethyl acetate. One or more of alkyl esters; hydrocarbons such as benzene and hexane; ethers such as diethyl ether; and halogenated alkanes such as dichloromethane and chloroform can be used. Among them, water, ethyl alcohol, and a mixed solvent of one or more of 1,3-butylene glycol are particularly suitable.
本発明に用いることのできる碁石茶抽出物の抽出方法は特に限定されないが、例えば乾燥したものであれば重量比で1〜1000倍量、特に10〜100倍量の溶媒を用い、常温抽出の場合には、0℃以上、特に20℃〜40℃で1時間以上、特に3〜7日間行うのが好ましい。また、60〜100℃で1時間、加熱抽出しても良い。また、10℃以下の抽出溶媒が凍結しない程度の温度で、1時間以上、特に1〜7日間抽出を行なっても良い。 The extraction method of the meteorite tea extract that can be used in the present invention is not particularly limited. For example, if it is dried, it is 1 to 1000 times by weight, particularly 10 to 100 times by weight, In this case, it is preferable to carry out at 0 ° C. or higher, particularly 20 ° C. to 40 ° C. for 1 hour or longer, particularly 3 to 7 days. Moreover, you may heat-extract at 60-100 degreeC for 1 hour. Further, the extraction may be performed at a temperature at which the extraction solvent at 10 ° C. or lower does not freeze for 1 hour or longer, particularly 1 to 7 days.
以上のような条件で得られる碁石茶抽出物は、抽出された溶液のまま用いても良いが、さらに必要により、濾過等の処理をして、濃縮、粉末化したものを適宜使い分けて用いることが出来る。 The meteorite tea extract obtained under the above conditions may be used as it is, but if necessary, use it after properly filtering and concentrating and pulverizing. I can do it.
本発明の各剤における碁石抽出物の配合量は、蒸発乾燥分に換算して0.00001〜20.0重量%が好ましく、特に0.001〜10.0重量%の範囲が最適である。 The blending amount of the meteorite extract in each agent of the present invention is preferably 0.00001 to 20.0% by weight, particularly in the range of 0.001 to 10.0% by weight, in terms of the evaporation dry matter.
本発明の各剤は、本発明の効果を損なわない範囲で、その他成分を併用することができる。 Each agent of the present invention can be used in combination with other components as long as the effects of the present invention are not impaired.
以下、本発明を実施例について具体的に説明するが、本発明はこれらの実施例により限定されるものではない。また、特記しない限り配合量は質量%で示す。また、特記しない限りエタノールは試薬特級(99.5%)を用いた。 EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not limited by these Examples. Unless otherwise specified, the blending amount is expressed in mass%. Unless otherwise specified, reagent special grade (99.5%) was used for ethanol.
<被験物質の調製>
乾燥植物原体に10倍の重量の50V/V%エタノール水溶液を加えて60℃、4時間加熱抽出した。抽出物の乾燥残分に対して、エタノール、水を重量比で1:2.5:96.5となるように加えて希釈したものを被験物質とした。なお用いた茶葉は、不発酵茶(緑茶、番茶、ほうじ茶)、茶葉を酸化酵素で半発酵させた半発酵茶(ウーロン茶)、茶葉を酸化酵素で完全発酵させた発酵茶(紅茶)、茶葉を酸化酵素および微生物により発酵させた後発酵茶(プーアール茶、碁石茶)である。
<Preparation of test substance>
A 10-fold weight 50V / V% aqueous ethanol solution was added to the dried plant material, and the mixture was extracted by heating at 60 ° C. for 4 hours. A test substance was prepared by diluting ethanol and water with a weight ratio of 1: 2.5: 96.5 to the dried residue of the extract. The tea leaves used were non-fermented tea (green tea, bancha, hojicha), semi-fermented tea (oolon tea) obtained by semi-fermenting tea leaves with oxidase, fermented tea (tea), tea leaves obtained by completely fermenting tea leaves with oxidase. It is a post-fermented tea (pu-erh tea, meteorite tea) fermented with oxidase and microorganisms.
<ニトロ化タンパク質分解活性試験>
ニトロ化タンパクの構成アミノ酸である3−ニトロチロシンをPBSに溶解し、0.005%(w/v)の濃度の溶液を調製した。PBSまたは3−ニトロチロシン溶液を96 well-plateに250 μLずつ分注し、被験物質および対照物質を各wellに終濃度が100 ppmになるよう添加した。37℃で72時間インキュベートしたのち、プレートリーダーにて450 nmの吸光度を測定した。
<Nitrated proteolytic activity test>
3-Nitrotyrosine, a constituent amino acid of nitrated protein, was dissolved in PBS to prepare a solution having a concentration of 0.005% (w / v). PBS or 3-nitrotyrosine solution was dispensed at 250 μL into 96 well-plates, and the test substance and the control substance were added to each well to a final concentration of 100 ppm. After incubating at 37 ° C. for 72 hours, the absorbance at 450 nm was measured with a plate reader.
図2より、対照物質(コントロール)および不発酵茶抽出物(緑茶、番茶、ほうじ茶)、半発酵茶(ウーロン茶)、発酵茶(紅茶)、後発酵茶(プーアール茶)では、ニトロ化タンパクの構成アミノ酸である3−ニトロチロシンの分解度は0〜7%程度に留まった。
一方、後発酵茶である碁石茶抽出物は、ニトロ化タンパクの構成アミノ酸である3−ニトロチロシン分解率は20%を超えた。以上のことから、碁石茶抽出物には、ニトロ化タンパクを分解する効果があることが示された。
Fig. 2 shows the composition of nitrated proteins in the control substance (control) and non-fermented tea extract (green tea, bancha, hojicha), semi-fermented tea (oolong tea), fermented tea (black tea), and post-fermented tea (pu-erh tea). The degree of degradation of 3-nitrotyrosine, an amino acid, remained at about 0-7%.
On the other hand, the meteorite tea extract, which is a post-fermented tea, had a degradation rate of 3-nitrotyrosine, which is a constituent amino acid of nitrated protein, exceeding 20%. From the above, it was shown that the meteorite tea extract has an effect of decomposing nitrated protein.
<抗酸化効果試験>
DPPH試験
<DPPH溶液の調製>DPPH溶液は、以下に示す各成分を、(A):(B):(C)=1:4:3容量の割合 で混合し調製する。
(A)MES(2-(N-モルホリノ)エタンスルホン酸)5.52 gを水100 mLに溶か し、1N−NaOHでPH6.1に調製する。
(B)DPPH(1,1−ジフェニルー2−ピクリルヒドラジル)15.7 mgをエタノール100 mLに溶解する。
(C)精製水
<Trolox溶液の調製> Trolox 25 mgをDMSO(ジメチルスルホキシド)10mLに溶解し、10mM 溶液を作成した。
<DPPH試験>10 μLの被験物質またはTrolox溶液(0.078 mM、0.156 mM、0.313 mM、0.625 mM、1.25 mM)を96 well plateの各well中に加え、次いでDPPH溶液190 μLを迅速に加え混合する。10分後、各wellの吸光度を540 nm で測定する。Trolox濃度と540 nmの吸光度値の検量線を作成し、被験物質の540 nmの吸光度から、被験物質のTrolox当量を算出した。
<Antioxidant effect test>
DPPH Test <Preparation of DPPH Solution> The DPPH solution is prepared by mixing the following components in a ratio of (A) :( B) :( C) = 1: 4: 3 volume.
(A) 5.52 g of MES (2- (N-morpholino) ethanesulfonic acid) is dissolved in 100 mL of water, and adjusted to pH 6.1 with 1N NaOH.
(B) 15.7 mg of DPPH (1,1-diphenyl-2-picrylhydrazyl) is dissolved in 100 mL of ethanol.
(C) Purified water
<Preparation of Trolox Solution> 25 mg of Trolox was dissolved in 10 mL of DMSO (dimethyl sulfoxide) to prepare a 10 mM solution.
<DPPH test> 10 μL of test substance or Trolox solution (0.078 mM, 0.156 mM, 0.313 mM, 0.625 mM, 1.25 mM) was added into each well of a 96 well plate, Quickly add 190 μL of DPPH solution and mix. After 10 minutes, the absorbance of each well is measured at 540 nm. A calibration curve of the Trolox concentration and the absorbance value of 540 nm was prepared, and the Trolox equivalent of the test substance was calculated from the absorbance of the test substance at 540 nm.
図3より、各被験物質の抗酸化力(Trolox等量)は、緑茶抽出物が最も高く、ついで紅茶抽出物、ほうじ茶抽出物、碁石茶抽出物の順であった。図2では、碁石茶抽出物のみにニトロ化タンパク構成アミノ酸である3−チロシン分解活性が認められたため、抗酸化力とニトロ化タンパク分解力には関係がないことが考えられた。同時に、碁石茶抽出物が他の茶類の抽出物とは全く異なる性質を有することが示唆された。 From FIG. 3, the antioxidant power (Trolox equivalent) of each test substance was highest in the green tea extract, followed by the black tea extract, the hoji tea extract, and the meteorite tea extract. In FIG. 2, since 3-tyrosine-degrading activity, which is a nitrated protein-constituting amino acid, was observed only in the meteorite tea extract, it was considered that there was no relationship between the antioxidant power and the nitrated proteolytic power. At the same time, it was suggested that Soseki tea extract has completely different properties from other tea extracts.
以下、本発明における各剤の処方例を示す。なお、含有量は質量%である。製法は、常法による。なお、処方は代表例であり、これに限定されない。また、処方例中の碁石茶抽出物の濃度は乾燥残分としての濃度である。 Hereinafter, the formulation example of each agent in this invention is shown. In addition, content is mass%. A manufacturing method is a conventional method. In addition, prescription is a representative example and is not limited to this. Moreover, the density | concentration of the meteorite tea extract in a prescription example is a density | concentration as a dry residue.
<処方例1:軟膏>
碁石茶抽出物(1,3ブチレングリコール50v/v%溶媒・60℃・4時間抽出) 0.1
レゾルシン 0.5
パラジメチルアミノ安息香酸オクチル 4.0
ブチルメトキシベンゾイルメタン 4.0
ステアリルアルコール 18.0
モクロウ 20.0
グリセリンモノステアリン酸エステル 0.3
ワセリン 33.0
香料 適 量
防腐剤・酸化防止剤 適 量
精製水 残 部
合 計 100.0
<Prescription Example 1: Ointment>
Meteorite tea extract (1,3 butylene glycol 50v / v% solvent, 60 ° C, 4 hours extraction) 0.1
Resorcin 0.5
Octyl paradimethylaminobenzoate 4.0
Butylmethoxybenzoylmethane 4.0
Stearyl alcohol 18.0
Owl 20.0
Glycerin monostearate 0.3
Vaseline 33.0
Perfume Appropriate amount Preservative / Antioxidant Appropriate amount Purified water balance Total 100.0
<処方例2:錠剤>
碁石茶抽出物 (エタノール50v/v%水溶液溶媒・25℃・3日抽出) 5.0
卵殻カルシウム 10.0
乳糖 20.0
澱粉 7.0
デキストリン 8.0
硬化油 5.0
セルロース 残部
合計 100.0
<Prescription Example 2: Tablet>
Soseki tea extract (ethanol 50v / v% aqueous solution, 25 ° C, 3 days extraction) 5.0
Eggshell calcium 10.0
Lactose 20.0
Starch 7.0
Dextrin 8.0
Hardened oil 5.0
Cellulose remaining total 100.0
<処方例3:栄養ドリンク>
碁石茶抽出物(水・60℃・4時間抽出) 1.0
タウリン 3.0
ピリドキシン塩酸塩 0.02
チアミン硫化物 0.01
リボフラビン 0.003
無水カフェイン 0.05
精製白糖 5.0
D−ソルビトール液 2.0
クエン酸無水物 0.2
香料 適量
精製水 残部
合計 100.0
<Prescription Example 3: Energy Drink>
Meteorite tea extract (water, 60 ° C, extracted for 4 hours) 1.0
Taurine 3.0
Pyridoxine hydrochloride 0.02
Thiamine sulfide 0.01
Riboflavin 0.003
Anhydrous caffeine 0.05
Purified white sugar 5.0
D-sorbitol solution 2.0
Citric anhydride 0.2
Perfume
Purified water balance 100.0
<処方例4:化粧水>
碁石茶抽出物(エタノール溶媒・5℃・1日抽出) 0.01
ポリオキシエチレンソルビタンモノラウレート(20E.O.) 1.5
1,3−ブチレングリコール 4.5
グリセリン 3.0
エタノール 2.0
ヒアルロン酸ナトリウム(1%水溶液) 5.0
エデト酸三ナトリウム 0.1
防腐剤 適量
pH調整剤 適量
精製水 残部
合計 100.0
<Formulation example 4: lotion>
Meteorite tea extract (ethanol solvent, 5 ° C, 1 day extraction) 0.01
Polyoxyethylene sorbitan monolaurate (20E.O.) 1.5
1,3-butylene glycol 4.5
Glycerin 3.0
Ethanol 2.0
Sodium hyaluronate (1% aqueous solution) 5.0
Edetate trisodium 0.1
Preservative appropriate amount pH adjuster appropriate amount purified water remaining balance 100.0
<処方例5:ファンデーション>
碁石茶抽出物(エタノール溶媒・25℃・1日抽出) 0.05
タルク 5.0
セリサイト 8.0
酸化チタン 5.0
色顔料 適 量
モノイソステアリン酸ポリグリセリル 3.0
ポリオキシエチレン硬化ヒマシ油 1.5
イソノナン酸イソトリデシル 10.0
1,3−ブチレングリコール 5.0
酸化防止剤 適 量
防腐剤 適 量
精製水 残 部
合 計 100.0
<Prescription Example 5: Foundation>
Meteorite tea extract (ethanol solvent, 25 ° C, extracted for 1 day) 0.05
Talc 5.0
Sericite 8.0
Titanium oxide 5.0
Color pigment Appropriate amount Polyglyceryl monoisostearate 3.0
Polyoxyethylene hydrogenated castor oil 1.5
Isotridecyl isononanoate 10.0
1,3-butylene glycol 5.0
Antioxidant appropriate amount Preservative appropriate amount Purified water balance Total 10.0
本発明によれば、碁石茶抽出物を用いることで、ニトロ化タンパク質を分解することが出来るので、ニトロ化タンパク質の生成に起因する各種症状を改善することが期待出来る。
According to the present invention, since the nitrated protein can be decomposed by using the meteorite tea extract, it can be expected to improve various symptoms caused by the production of nitrated protein.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016072475A JP6557166B2 (en) | 2016-03-31 | 2016-03-31 | Nitrated proteolytic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016072475A JP6557166B2 (en) | 2016-03-31 | 2016-03-31 | Nitrated proteolytic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017178899A JP2017178899A (en) | 2017-10-05 |
JP6557166B2 true JP6557166B2 (en) | 2019-08-07 |
Family
ID=60005101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016072475A Active JP6557166B2 (en) | 2016-03-31 | 2016-03-31 | Nitrated proteolytic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6557166B2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3704498B2 (en) * | 2001-11-22 | 2005-10-12 | 株式会社コーセー | Skin preparation |
JP2009183272A (en) * | 2008-02-11 | 2009-08-20 | Nagao Kitamura | Method for producing goishi-tea |
JP2015224203A (en) * | 2014-05-26 | 2015-12-14 | 学校法人同志社 | Protein glycation reaction inhibitor |
JP2017048152A (en) * | 2015-09-03 | 2017-03-09 | 株式会社ダイセル | Anti-glycation agent comprising fermented tea extract |
-
2016
- 2016-03-31 JP JP2016072475A patent/JP6557166B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017178899A (en) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10092493B2 (en) | Composition of skin external application for anti-aging | |
US9132294B2 (en) | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | |
KR101746843B1 (en) | Use of a polyphenol-rich plant extract as antioxidant in combination with a hydrating or humectant agent | |
US10695284B2 (en) | Skin external composition for skin moisturization containing red yeast rice extract | |
EP3509707B1 (en) | Aqueous extract of prunus persica and process for preparing the same | |
JP2006241036A (en) | Anti-aging cosmetic | |
EP2200574B1 (en) | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same | |
JP2011088845A (en) | Involucrin expression inhibitor | |
US20090170788A1 (en) | Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose | |
JP2006241148A (en) | Collagenase inhibitor and external preparation for skin for preventing aging | |
KR101805872B1 (en) | Cosmetic composition for improving skin wrinkle containing plant extract removed chlorophyll | |
KR101552472B1 (en) | Method for producing Crassostrea gigas extract with increased antioxidant and whitening activity | |
KR102525467B1 (en) | Skin external application composition for anti-aging containing Rhodotypos scandens extract | |
KR101616284B1 (en) | Anti-skin aging or Anti-wrinkle Cosmetic composition comprising specific herbal extracts | |
JP6557166B2 (en) | Nitrated proteolytic agent | |
JP2014172859A (en) | Cosmetic | |
Kardono et al. | Development of Papaya Latex, Papaya Extract (Carica papaya L.) and Yam Bean Tuber Extract (Pachyrrhizus erosus (L.) Urb.) for Skin Lightening Lotion Based on Tyrosinase Inhibition and Antioxidant Activities | |
US10987397B2 (en) | Catechin-free tea water and composition containing same | |
KR102525091B1 (en) | A cosmetic compositon for pore-minimizing comprising natural complex extract as an active ingredient | |
JP7122169B2 (en) | Melanin degradation accelerator and whitening cosmetic | |
AU2018226144B2 (en) | Method for producing cosmetic composition using skin cosmetic solution | |
KR102628074B1 (en) | skin external application composition for anti-aging containing Luzula capitate extract | |
JP2021147335A (en) | Nitrated protein decomposer | |
KR20230160232A (en) | Extract of upper growth of holy basil, and cosmetic or dermatological composition containing same | |
KR20230103481A (en) | Cosmetic composition containing extracts from Poria Cocos and purified snake venom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190709 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190711 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6557166 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |